Advertisment
|
|
|
news roundup
Britain's unprecedented vote to leave the EU will have major ramifications for biopharma, including in areas such as drug regulation and R&D.
|
advertisment
Unlock the full potential of RBM using this new framework which integrates EDC with advanced RBM tools and goes beyond identifying risk to enable immediate action!
 Listen to this podcast to learn how
|
IRB-Copernicus Group has acquired clinical trials information provider CenterWatch, and added its founder and owner, Ken Getz, to WCG's board of directors.
BBK Worldwide has struck a deal with Apptomics to develop a new suite of mobile applications for patients, caregivers, physicians and payers.
|
advertisment
Transforming Patient Recruitment through Patient and Site Engagement
Live Webinar: Tuesday, August 23, 2016 at 11 am – 12 noon EDT
 Register now
|
Read more about product releases at DIA, as well as exhibitor profiles, speakers, blogs and podcasts with DIA presenters.
|
|
|
advertisment 
|
|
|
advertisment
The State of Risk-based Monitoring (RBM)
On Demand
 Learn more
|
Subscribe
|
Stay connected with Applied Clinical Trials and sign up for your print or digital issues, as well as our enewsletters.
Subscription offers »
|
|
|
|
Articles
Trial design innovation in immuno-oncology will continue to be molecularly driven, focusing on understanding the genomic aberrations of patients—with collaboration and big data playing prominent roles.
A look at the EMA's recently launched PRIority MEdicines (PRIME) drug approval scheme, which hopes to build upon existing regulations in Europe to support product development in cases of unmet medical need.
|
|
Blog Posts
Ken Getz of the Tufts Center for the Study of Drug Development discusses how better integration of health data and technology will be critical to future gains for clinical research.
Planning ahead can save time and money later, thanks to recent regulatory changes in cardiac safety guidance.
|
|
RBM
Outlining those technology solutions best poised to raise the data and process quality of risk-based monitoring and remote trial management.
Highlighting the key steps in developing a risk-management process to create an RBM plan—ideally during the study design phase.
In the final entry in a three-part series on ensuring compliance with the ICH E6 (R2) Addendum to take effect later this year, the value of embracing a centralized, technology-driven approach to RBM is explored.
|
|
|
|
|
|
Read the digital edition of Applied Clinical Trials
Click here to sign up or renew your subscription
|
|
|
|
|
